ArticlePloS one2026
Equity premium forecasting with reliability-screened forward-looking signals.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Forecasting the equity risk premium is challenging because predictive relationships are unstable out of sample. We propose a two-stage framework that generates forward-looking signals from standard macro-financial predictors and admits them only when they satisfy predictor-level reliability criteria. In Stage 1, each predictor is forecast one step ahead to obtain an expected movement and an uncertainty proxy. In Stage 2, lagged predictors are augmented with the admitted signals and mapped into next-period excess returns using random forests, optionally combined with SHAP-guided screening and dimension reduction. Using monthly U.S. data from 1952 to 2024, we evaluate both benchmark-relative out-of-sample accuracy and the economic value of forecasts in a constrained mean-variance allocation. Selective admission improves out-of-sample accuracy and, in selected specifications, yields economically meaningful gains in risk-adjusted performance and drawdown control. Tail-conditional diagnostics show that these gains are concentrated disproportionately in downside market states, helping explain when statistical improvements translate into economic value. The main qualitative patterns remain robust across alternative learners, across the S&P 500 and the CRSP value-weighted market index, and under net of transaction cost evaluation and alternative portfolio volatility checks. Taken together, the findings suggest that forward-looking predictor information is most useful when admitted selectively on the basis of predictor-level reliability, with its practical value lying less in universal forecast improvements than in more robust and downside-sensitive equity premium forecasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.